Skip to content
Evigrade
ModerateDirect oral anticoagulants (factor Xa inhibitors)×Analgesics and antipyretics. Pyrazolones

Updated · Methodology

Mechanism

The liver breaks down apixaban mainly through CYP3A4/5, and apixaban is a substrate of the transporters P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) (apixaban summary of product characteristics, SmPC, European Medicines Agency, EMA). Metamizole can induce the enzymes CYP2B6 and CYP3A4 and lower the levels of drugs they metabolise, but apixaban is not on that list. The SmPCs do not state how strong this induction is or whether metamizole affects P-gp (metamizole SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Strong inducers of both CYP3A4 and P-gp cut apixaban exposure by about half. In a study in atrial fibrillation, they were linked with lower efficacy and more bleeding (apixaban SmPC, EMA). Pyrazolones, the group metamizole belongs to, may interact with oral anticoagulants, but it is not known to what extent this applies to metamizole itself (metamizole SmPC, AEMPS). Metamizole is classified as a pyrazolone, not a non-steroidal anti-inflammatory drug. Its SmPC says nothing about its own effect on platelets, only that it may reduce the antiplatelet effect of acetylsalicylic acid (metamizole SmPC, AEMPS).

Symptoms

Common signs of bleeding with apixaban are bruising, nosebleeds and haematomas. Gastrointestinal bleeding, blood in the urine or stool, vaginal bleeding and anaemia also occur (apixaban summary of product characteristics, SmPC, European Medicines Agency, EMA). Gastrointestinal bleeding has occurred with metamizole, and many of these patients were also taking non-steroidal anti-inflammatory drugs or had taken an overdose. Thrombocytopenia is very rare (metamizole SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Signs of a blood disorder with metamizole include malaise, fever, sore throat, painful sores in the mouth or nose, bruising, bleeding and pallor (metamizole SmPC, AEMPS). If apixaban levels fall, the risk of stroke and other thromboembolic events rises (apixaban label, US Food and Drug Administration, FDA).

Management

No SmPC or label contraindicates this combination or names the pair. With apixaban, monitor the patient carefully for any sign of bleeding and use apixaban with caution in situations with a higher bleeding risk. Stop it in case of severe bleeding (apixaban summary of product characteristics, SmPC, European Medicines Agency, EMA). Teach the patient the signs of blood loss and ask them to report these at once (apixaban label, US Food and Drug Administration, FDA). If bruising, bleeding, pallor, fever, sore throat or mouth sores appear, stop metamizole immediately. Do a complete blood count with differential at once and repeat it until the values return to normal (metamizole SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). If the patient also takes low-dose acetylsalicylic acid for heart protection, use metamizole with caution, because it may reduce the antiplatelet effect of acetylsalicylic acid (metamizole SmPC, AEMPS). The strict apixaban rules apply only to strong inducers of both the enzyme CYP3A4 and P-glycoprotein. Do not use apixaban with them to treat deep vein thrombosis or pulmonary embolism, and use it with caution in the other indications (apixaban SmPC, EMA). The US label advises avoiding such combinations (apixaban label, FDA). No document places metamizole among these inducers or gives an apixaban dose change for it. In older patients and in kidney or liver impairment, give metamizole only after weighing benefit and risk (metamizole SmPC, AEMPS).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Apixaban

Other interactions with Metamizole sodium